Details for Patent: 9,796,741
✉ Email this page to a colleague
Which drugs does patent 9,796,741 protect, and when does it expire?
Patent 9,796,741 protects VOYDEYA and is included in one NDA.
This patent has one hundred and four patent family members in twenty-four countries.
Summary for Patent: 9,796,741
| Title: | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
| Abstract: | Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein Ror Ron the A group is an aryl, heteroaryl or heterocycle (R) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer. |
| Inventor(s): | Gadhachanda Venkat Rao, Wang Qiuping, Pais Godwin, Hashimoto Akihiro, Chen Dawei, Wang Xiangzhu, Agarwal Atul, Deshpande Milind, Wiles Jason Allan, Phadke Avinash S. |
| Assignee: | Achillion Pharmaceuticals, Inc. |
| Application Number: | US14631625 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 9,796,741
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alexion Pharms Inc | VOYDEYA | danicopan | TABLET;ORAL | 218037-001 | Mar 29, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB | ⤷ Sign Up | |||
| Alexion Pharms Inc | VOYDEYA | danicopan | TABLET;ORAL | 218037-002 | Mar 29, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,796,741
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015223068 | ⤷ Sign Up | |||
| Australia | 2015223072 | ⤷ Sign Up | |||
| Australia | 2015223075 | ⤷ Sign Up | |||
| Australia | 2015223084 | ⤷ Sign Up | |||
| Australia | 2015223121 | ⤷ Sign Up | |||
| Australia | 2015223132 | ⤷ Sign Up | |||
| Australia | 2020260434 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
